24 Sep 2021 11:10
AIM WINNERS & LOSERS: In The Style shares shredded by profit warning
AIM WINNERS & LOSERS: In The Style shares shredded by profit warning
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Imperial Innovations Group Share News (IVO)
IVO Share
Price
IVO Share
News
IVO Share
Chat
IVO Share
Trades
IVO
Live RNS
IVO Share
Charts
IVO Broker
Ratings
IVO Directors
Deals
IVO Financial
Diary
IVO
Fundamentals
IVO Short
Positions
IVO
Media
Imperial Innovations Group Information
- There is currently no data for IVO
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Imperial Innovations celebrates investment momentum
Mon, 24th Oct 2016 15:04
(ShareCast News) - Imperial Innovations Group noted on Monday that its portfolio company, Veryan Medical, has completed enrolment into the MIMICS-2 clinical study of its BioMimics 3D Self-Expanding Stent System.The AIM-traded firm said the MIMICS-2 study is a prospective, multicentre, interventional study designed to evaluate the safety and effectiveness of Veryan's patented three dimensional helical stent in the treatment of patients with symptomatic femoropopliteal disease.It said the study is being conducted under a US Food and Drug Administration Investigational Device Exemption (IDE), with Japanese Pharmaceuticals and Medical Devices Agency concurrence under the 'Harmonisation By Doing' initiative, in order to provide safety and effectiveness data to support future marketing applications for BioMimics 3D in both the US and Japan.BioMimics 3D has previously been awarded the CE Mark and is actively being sold across Europe, Imperial's board reported.Enrolment in the MIMICS-2 study concluded with a total of 271 patients enrolled across 47 investigational sites in Germany, the US and Japan.As at 31 July 2016, Imperial Innovations had a 46.1% interest in the issued share capital of Veryan with a net investment carrying value of £26.5m."Completion of enrolment into the MIMICS-2 is an important milestone for Veryan on its path to the global commercialisation of its unique stent technology," said Imperial Innovations chief investment officer Dr Nigel Pitchford."We are very pleased with the speed at which enrolment has been completed, which is a testament to the investigating physicians' enthusiasm for recruiting patients and the efficiency of the Veryan team."
More News
5 Jan 2017 16:45
Imperial Innovations completes quick-change to Touchstone
(ShareCast News) - Imperial Innovations Group announced on Thursday that, further to the shareholder approval received at its AGM on 21 November 2016, the change of the company's name to Touchstone Innovations took effect on 4 January. The AIM-traded firm added that, with effect from 0800 GMT on Thu
Read more28 Oct 2016 14:18
Imperial Innovations to change name to 'Touchstone'
(ShareCast News) - Imperial Innovations Group announced on Friday that at its annual general meeting on 21 November, it will be seeking shareholder approval to change the name of the company to Touchstone Innovations. The AIM-traded group was originally formed as the technology transfer office for I
Read more13 Oct 2016 08:36
Imperial Innovations' increases investments as pre-tax loss widens
(ShareCast News) - Imperial Innovations' annual pre-tax loss widened while the technology commercialisation and investment company increased investments across its business with universities and a joint venture. For the year ended 31 July, the pre-tax loss widened to £63.1m from £15.1m, last year, w
Read more6 Oct 2016 15:15
6 Oct 2016 15:15
Imperial Innovations shares up on portfolio company progress
(ShareCast News) - Imperial Innovations Group updated the market on Thursday, noting that its portfolio company TopiVert Pharma has announced that the first patients have been dosed in its Phase IIa proof-of-concept study to evaluate the safety, tolerability and efficacy of a rectal formulation of T
Read more3 Oct 2016 15:20
Imperial Innovations sells Permasense portfolio business
(ShareCast News) - AIM-listed Imperial Innovations has sold its portfolio company Permasense to Fortune 500 company Emerson Electric for an initial consideration of £30.6m in cash. Further amounts of up to £10m may be paid in addition, subject to the Permasense business achieving certain performance
Read more21 Sep 2016 12:23
Imperial Innovations invests £5.1m in new biotech start-up
(ShareCast News) - AIM-listed technology investor Imperial Innovations invested £5.1m in Artios Pharma, a new biotech start-up launched on Wednesday. Imperial Innovations contributed £5.1m to the £25m series A funding round, giving it a 14.9% interest in the new Cambridge- based company. Artios, wh
Read more19 Aug 2016 09:23
Cambridge University innovation investor raises 75 million pounds
LONDON, Aug 19 (Reuters) - Cambridge Innovation Capital, which commercializes technology and healthcare research from Cambridge University, has raised 75 million pounds ($98 million) from investors, including for the first time Woodford Investment Management. CIC, founded in 2013, has alrea
Read more